FDA Accepts Sanofi’s Tzield SBLA Priority Review To Expand Use In Children 1+ For Type 1 …

In overnight trading at 12:43 AM EST, the stock rose to $49.58, gaining $1.35 or 2.80%. For More Such Health News, visit rttnews.com. For comments and …